Skip to main content
Clinical Trials/NCT04364906
NCT04364906
Completed
Not Applicable

Comparison of the Effects of Quadratus Lumborum Block 2 and 3 (QLB 2 and QLB 3) on Post-operative Analgesia in Cesarean Section Surgery

Ondokuz Mayıs University1 site in 1 country80 target enrollmentApril 29, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Analgesia
Sponsor
Ondokuz Mayıs University
Enrollment
80
Locations
1
Primary Endpoint
Opioid consumption in the first 24 hours after surgery
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This study evaluates the post-operative analgesic effects of quadratus lomborum block 2 and 3 (QLB 2, 3) in patients having cesarean section with spinal anesthesia. Spinal anesthesia will be performed to all patients for the surgery.

Detailed Description

In this study, patients are divided into two groups. After the spinal anesthesia is performed and cesarean section surgery is over; QLB 2 block will be performed to patients in Group A ; while QLB 3 block will be performed to patients in Group B. In addition, patient controlled analgesia (PCA) will be used in the first 24 hours postoperatively. Group A - Patients in group A will have QLB 2 block after the surgery. In addition, patient controlled analgesia (PCA) will be used in the first 24 hours postoperatively. Group B - Patients in group B will have QLB 3 block after the surgery. In addition, patient controlled analgesia (PCA) will be used in the first 24 hours postoperatively.

Registry
clinicaltrials.gov
Start Date
April 29, 2020
End Date
September 15, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Ondokuz Mayıs University
Responsible Party
Principal Investigator
Principal Investigator

Caner Genç

Medical Doctor

Ondokuz Mayıs University

Eligibility Criteria

Inclusion Criteria

  • Being pregnant for at least 37 weeks
  • Planning an elective cesarean operation
  • Being between the ages of 18-45

Exclusion Criteria

  • ASA 3-4 patients with comorbitidies (Serious renal, cardiac, hepatic disease)
  • Being operated with general anesthesia
  • Obesity (\> 100 kg, BMI\> 35 kg / m2)
  • Contraindication of regional anesthesia (quagulopathy, abnormal INR, thrombocytopenia, infection at the injection site)
  • Hypersensitivity to local anesthetics or a history of allergy
  • Patients with a history of opioid use longer than four weeks
  • Patients with psychiatric disorders
  • Patients with anatomic deformity
  • Patients who do not want to participate

Outcomes

Primary Outcomes

Opioid consumption in the first 24 hours after surgery

Time Frame: 1 day

Morphine consumption in the first 24 hours will be counted by IV patient controlled analgesia device (PCA). Patients will be able to request opioids via PCA device when the nrs score is above 4.

Secondary Outcomes

  • Post-operative acute pain(1 day)

Study Sites (1)

Loading locations...

Similar Trials